TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in HbA1c from baseline to week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Lean Body Mass (LBM) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of antiosteoporotic medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-hour postdose FEV1 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to DMARD prescription
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EADO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: H. pylori cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stimulated salivary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall GSRS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Onset of adequate sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for active airway management
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted mean total symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total scores in the RQLQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: gastrointestinal-specific anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: survival from colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: risk of recurrent parasitaemia on day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First occurrence of MACE
Endpoint domain: Mortality/survival
Primary endpoint: Clinical cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion of CBT group therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Higher levodopa dose per kilogram body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of LTFU
Endpoint domain: Mortality/survival
Primary endpoint: Maximal muscle power (PMAX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal RPM (RPMopt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CG100649
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of CG100649
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AA/EPA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of Grade 2 acute xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of Grade 2 late xerostomia
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in facial activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High levels of plasma interleukin (IL)-6, IL-8, IL-10, and soluble tumor necrosis factor (TNF) receptor type II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of endotoxin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dysregulated production of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: energy intake at lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appetite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Physical Performance Battery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Timed up‐and‐go
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: surgery time
Endpoint domain: Resource use
Primary endpoint: reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reported hypersensitivity to electricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxidative status in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of carotid stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Gluteus maximus recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hamstring recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of excretion of ampicillin and cloxacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum excretion rates (dDu/dt max) for ampicillin and cloxacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum inhibitory concentration (MIC) of ampicillin and cloxacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cardiac death, MI, stroke, definite/probable stent thrombosis, and BARC type 3 or 5 bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in nociceptive perception (pain threshold and rating)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CHEP amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fat percentage change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume normal daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Device longevity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing-related estimated costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total PCO index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Nd:YAG laser treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tympanostomy tube occlusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERN amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FRN amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in oral health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in child tooth brushing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in oral health fatalism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left Ventricular Mass Index (LVMi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Atrial Volume Index (LAVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fistula obliteration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient neurological morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean concentrations of antibody to pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease activity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of antimicrobials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Normalization of C-reactive protein and sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental reports of bronchitis
Endpoint domain: Adverse events/effects
Primary endpoint: Lower respiratory tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Antipyretics use
Endpoint domain: Resource use
Primary endpoint: HER2 phosphorylation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patterns of psychiatric comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychosocial and psychoeducational dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cognitive deficits
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of reliable and clinically significant improvement (RCSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal oxygen desaturation during second stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of > or =2‐min epochs of fetal oxygen saturation <30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Years free of CVD
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean standardized BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daclizumab HYP clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absorption time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of IP-10/CXCL10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proposition and hierarchy scores for concept maps
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AT‐III levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Liver enzyme levels (ALT, AST, GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of anxiety and depressive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate in ELISPOT assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induced proliferative responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in central DME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-to-first occurrence of end-stage renal disease or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: perceived back pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: incidence of haematomas ≥ 5 cm
Endpoint domain: Adverse events/effects
Primary endpoint: Positive Yc‐PCR result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pruritus intensity difference >= 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in BHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of Der p 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of Der p 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of unmaintained remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: morphine analogue requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient-controlled epidural analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postoperative pain scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: AUC 0-infinity of theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of theophylline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of oral theophylline
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Auditory reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-assessment of driving safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Integrative motor function of extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower genital colonization with U. urealyticum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vertical transmission of U. urealyticum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical quality of life at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Decrease in cytokine levels (TNF-alpha and IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in C-reactive protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of hyperdynamic cardiovascular state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma IGF‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abdominal pain < 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abdominal pain > 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual analog scale (VAS) values of short‐lasting abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of combined endpoints of mortality and morbidity
Endpoint domain: Mortality/survival
Primary endpoint: overall incidence of end-point events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative endometritis
Endpoint domain: Adverse events/effects
Primary endpoint: Knodell's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: HCV RNA negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean nighttime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean nighttime diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Night/day ratio for systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Night/day ratio for diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: femoral head perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean distance from the reamer path to the deep MFCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean terminal superior retinacular vessels damaged
Endpoint domain: Adverse events/effects
Primary endpoint: mean time to progression of pre-existing bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: formation of new bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time to occurrence of new bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean change in ADSoS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Peak BUN and creatinine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Erroneous reporting of SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erroneous reporting of DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erroneous reporting of HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of serum urate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of urine urate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time free of skeletal-related events (SREs)
Endpoint domain: Mortality/survival
Primary endpoint: Pain reduction at 1 month (BPI worst score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net adverse clinical events (NACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of TNF-alpha and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bolus dose of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ICP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficiency of the diagnostic process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of nursing diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regular exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: sustained azoospermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Drained blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in traumatic stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative infectious/wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: total number of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: episodes of severe or unbearable pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant prolongation of QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nasal stuffiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum sMR concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heightened alcohol stimulation and reward sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Deviation of NN intervals (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone mineral accretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk for osteopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of cholesterol and bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of dietary counseling steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-perceived preparedness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in having an effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bowel-cleansing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ADR (adenoma detection rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Final anatomical success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective wellness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force of contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain relief during cough and mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on PAID scale
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: YMRS score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Impressions‐Mania score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perioperative myocardial infarctions
Endpoint domain: Mortality/survival
Primary endpoint: absolute liver blood flow index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEGX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalized propofol infusion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes